# Relates to requiring certain health insurance issuers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale

**Bill ID:** A1962A
**Session:** 2023
**Sponsor:** Latrice Walker
**Status:** In Assembly Committee

## Summary

Requires certain health insurance issuers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale.

---

## Full Text

S T A T E  O F  N E W  Y O R K
 ________________________________________________________________________
 
  1962
 
  2023-2024 Regular Sessions
 
  I N  A S S E M B L Y
 
  January 23, 2023
  ___________
 
 Introduced by M. of A. WALKER -- read once and referred to the Committee
  on Insurance
 
 AN  ACT  to amend the insurance law, in relation to requiring individual
  and small group insurance carriers and group and blanket accident  and
  health  carriers  to  certify that at least a majority of prescription
  drug rebates are provided to patients at the point of sale
 
  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
  Section 1. Paragraph 1 of subsection (e) of section 3231 of the insur-
 ance law is amended by adding a new subparagraph (C) to read as follows:
  (C)  AN  INSURER SHALL ANNUALLY CERTIFY TO THE DEPARTMENT THAT, DURING
 THE PRIOR BENEFIT YEAR, THE INSURER MADE AVAILABLE TO ENROLLEES  AT  THE
 POINT  OF SALE AT LEAST A MAJORITY (I.E., GREATER THAN FIFTY PERCENT) OF
 THE REBATES RECEIVED BY SUCH INSURER OR ANY  THIRD  PARTY  ADMINISTERING
 PRESCRIPTION DRUG BENEFITS ON BEHALF OF SUCH INSURER.
  (I) FOR PURPOSES OF THIS PARAGRAPH, "REBATE" MEANS:
  (1)  NEGOTIATED  PRICE  CONCESSIONS  INCLUDING BUT NOT LIMITED TO BASE
 REBATES AND REASONABLE ESTIMATES OF ANY  PRICE  PROTECTION  REBATES  AND
 PERFORMANCE-BASED  REBATES THAT MAY ACCRUE DIRECTLY OR INDIRECTLY TO THE
 ISSUER DURING THE COVERAGE YEAR FROM A MANUFACTURER, DISPENSING  PHARMA-
 CY, OR OTHER PARTY TO THE TRANSACTION, AND
  (2)  REASONABLE  ESTIMATES  OF ANY FEES AND OTHER ADMINISTRATIVE COSTS
 THAT ARE PASSED THROUGH TO THE ISSUER AND SERVE TO REDUCE  THE  ISSUER'S
 PRESCRIPTION DRUG LIABILITIES FOR THE COVERAGE YEAR.
  (II)  IN PROVIDING THE CERTIFICATION REQUIRED UNDER THIS SUBPARAGRAPH,
 AN ISSUER SHALL NOT PUBLISH OR OTHERWISE  REVEAL  INFORMATION  REGARDING
 THE ACTUAL AMOUNT OF REBATES THE ISSUER RECEIVED ON A PRODUCT-, MANUFAC-
 TURER-  OR  PHARMACY-SPECIFIC  BASIS. SUCH INFORMATION IS PROTECTED AS A
 TRADE SECRET, IS NOT A PUBLIC RECORD AS DEFINED IN THE  PUBLIC  OFFICERS
 LAW  AND SHALL NOT BE DISCLOSED DIRECTLY OR INDIRECTLY. AN INSURER SHALL
 IMPOSE THE CONFIDENTIALITY PROTECTIONS OF THIS SUBPARAGRAPH ON ANY THIRD
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
  [ ] is old law to be omitted.
  LBD05427-02-3
 A. 1962  2
 
 PARTIES OR VENDORS WITH WHICH IT CONTRACTS  THAT  MAY  RECEIVE  OR  HAVE
 ACCESS TO REBATE INFORMATION.
  ยง 2. Subsection (b) of section 3221 of the insurance law is amended to
 read as follows:
  (b)  (1)  No  such policy shall be delivered or issued for delivery in
 this state unless a schedule of the premium  rates  pertaining  to  such
 form shall have been filed with the superintendent.
  (2)  AN  INSURER SHALL ANNUALLY CERTIFY TO THE DEPARTMENT THAT, DURING
 THE PRIOR BENEFIT YEAR, THE INSURER MADE AVAILABLE TO ENROLLEES  AT  THE
 POINT  OF SALE AT LEAST A MAJORITY (I.E., GREATER THAN FIFTY PERCENT) OF
 THE REBATES RECEIVED BY SUCH INSURER OR ANY  THIRD  PARTY  ADMINISTERING
 PRESCRIPTION DRUG BENEFITS ON BEHALF OF SUCH INSURER.
  (A) FOR PURPOSES OF THIS PARAGRAPH, "REBATE" MEANS:
  (I)  NEGOTIATED  PRICE  CONCESSIONS  INCLUDING BUT NOT LIMITED TO BASE
 REBATES AND REASONABLE ESTIMATES OF ANY  PRICE  PROTECTION  REBATES  AND
 PERFORMANCE-BASED  REBATES THAT MAY ACCRUE DIRECTLY OR INDIRECTLY TO THE
 ISSUER DURING THE COVERAGE YEAR FROM A MANUFACTURER, DISPENSING  PHARMA-
 CY, OR OTHER PARTY TO THE TRANSACTION, AND
  (II)  REASONABLE  ESTIMATES OF ANY FEES AND OTHER ADMINISTRATIVE COSTS
 THAT ARE PASSED THROUGH TO THE ISSUER AND SERVE TO REDUCE  THE  ISSUER'S
 PRESCRIPTION DRUG LIABILITIES FOR THE COVERAGE YEAR.
  (B) IN PROVIDING THE CERTIFICATION REQUIRED UNDER THIS SUBDIVISION, AN
 ISSUER  SHALL  NOT PUBLISH OR OTHERWISE REVEAL INFORMATION REGARDING THE
 ACTUAL AMOUNT OF REBATES THE ISSUER RECEIVED ON A PRODUCT-,  MANUFACTUR-
 ER- OR PHARMACY-SPECIFIC BASIS. SUCH INFORMATION IS PROTECTED AS A TRADE
 SECRET, IS NOT A PUBLIC RECORD AS DEFINED IN THE PUBLIC OFFICERS LAW AND
 SHALL  NOT  BE DISCLOSED DIRECTLY OR INDIRECTLY. AN INSURER SHALL IMPOSE
 THE CONFIDENTIALITY PROTECTIONS OF THIS SUBDIVISION ON ANY THIRD PARTIES
 OR VENDORS WITH WHICH IT CONTRACTS THAT MAY RECEIVE OR  HAVE  ACCESS  TO
 REBATE INFORMATION.
  ยง 3. This act shall take effect immediately.